About: Helus Pharma Inc., doing business as Helus Pharma, operates as a clinical stage pharmaceutical company that focuses on developing therapies to treat psychiatric and neurological conditions. It develops HLP003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder; and HLP004, a deuterated N, N-dimethyltryptamine, which is in phase 2 clinical trial for treating generalized anxiety disorders. The company's preclinical product includes HLP005, a phenethylamine and tryptamine derivative to treat central nervous system. It has a strategic partnership agreement with Segal Trials to evaluate HLP003 for the adjunctive treatment of major depressive disorder; and Osmind for mental health treatments. The company was formerly known as Cybin Inc. and changed its name to Helus Pharma Inc. in October 2026. The company was founded in 2019 and is headquartered in Toronto, Canada.
Sector: Healthcare
Industry: Biotechnology
Latest price: $10.72 (+2.00%)
HELP NYSE Cybin Inc.
Cybin Inc. share price
HELP price activity
Último preço
$ 10,720
Variação (24h)
0,21 USD (2,00%)
Volume
1.10M
Volume (média 4 sem.)
-
Abertura
$ 10,50
Variação do dia
$ 10,19 - $ 10,79
Fechamento anterior
$ 10,51
Último negócio
08 Oct, 8:27 pm GMT+0
Atrasado
08 Oct, 8:27 pm GMT+0
HELP price performance
Atrasado
08 Oct, 8:27 pm GMT+0
quote.marketSignals